Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101
Lotus Pharmaceuticals, NRx Pharmaceuticals and Alvogen have entered a global collaboration deal to develop and commercialise NRX-101 for suicidal treatment-resistant …
USPTO issues notice of allowance for Enveric’s EVM301 series
The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for Enveric Biosciences’ patent application for …
Alkeus raises funds to launch Stargardt disease therapy gildeuretinol
Alkeus Pharmaceuticals has raised $150m in Series B financing to support the registration and launch of gildeuretinol (ALK-001) to treat …
Magazine: The journey of first generics
In a 2022 annual report, the US Food and Drug Administration’s (FDA) Office of Generic Drugs stated it had approved …
Avadel Pharmaceuticals launches excessive daytime sleepiness therapy in US
Avadel Pharmaceuticals has introduced LUMRYZ (sodium oxybate) for commercial use in the US to treat cataplexy (excessive daytime sleepiness, or …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Selvita and the University of Oxford join forces to tackle Parkinson’s disease
The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance …
ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data
Summit Therapeutics has announced data for its novel investigational bispecific antibody, ivonescimab, known as SMT112 or AK112 in a non-small …
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …
ITM raises $273 million to fund radionuclide therapy pipeline
ITM (Isotope Technologies Munich) has announced a €255 million ($273.16 million) equity investment funding raise. According to ITM’s CEO Steffen …
Simurosertib by Millennium Pharmaceuticals for Rectal Cancer: Likelihood of Approval
Simurosertib is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Rectal Cancer. According to GlobalData, Phase …
IXC-103 by Ixchel Pharma for Friedreich Ataxia: Likelihood of Approval
IXC-103 is under clinical development by Ixchel Pharma and currently in Phase I for Friedreich Ataxia. According to GlobalData, Phase …
BGB-3245 by MapKure for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
BGB-3245 is under clinical development by MapKure and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, …
BGB-3245 by MapKure for Endometrial Cancer: Likelihood of Approval
BGB-3245 is under clinical development by MapKure and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I …
Telitacicept by RemeGen for Antiphospholipid Syndrome: Likelihood of Approval
Telitacicept is under clinical development by RemeGen and currently in Phase II for Antiphospholipid Syndrome. According to GlobalData, Phase II …
BGB-3245 by MapKure for Melanoma: Likelihood of Approval
BGB-3245 is under clinical development by MapKure and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs …